The effect of fibratestatin combination therapy on cardiovascular events: A retrospective cohort analysis

Current Medical Research and Opinion

Volumn 26, Issue 9, 2010, Pages 2141-2146

  Wierzbicki, Anthony S ^a,b   Morrell, Jonathan ^a   Hemsley, Deborah ^a   McMahon, Zofia ^b   Crook, Martin A ^b   Wray, Richard ^a  

^a St Leonards on Sea   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiovascular risk; Cholesterol; Coronary heart disease; Fibrate; Statin; Triglycerides

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CIPROFIBRATE; CLOPIDOGREL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; HYPERTENSION; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SMOKING; STROKE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; CARDIOVASCULAR DISEASE; DRUG COMBINATION; EVALUATION; INCIDENCE; MIDDLE AGED;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; FIBRIC ACIDS; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77955618662     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.503429     Document Type: Article

References (33)

1. Wierzbicki AS, Graham CA, Young IS, et al. Familial combined hyperlipidaemia: under-defined and under-diagnosed? Curr Vasc Pharmacol 2008; 6:13-22
2. Hopkins PN, Wu LL, Hunt SC, et al. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 2005;45:1003-1012
3. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl. V):v1-v52
4. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001; 285:2486-2497
5. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102:1K-34K
6. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010;375:181-183
7. Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol 2009;24:372-379
8. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003;19:155-168
9. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462-468
10. Fievet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol 2009;20:505-511
11. Tziomalos K, Athyros VG, Karagiannis A, et al. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets 2009;10:320-327
12. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418
13. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
14. Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325:1139
15. Gardette V, Bongard V, Dallongeville J, et al. Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort). Am J Cardiol 2009;103:381-386
16. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006;5:145-156
17. Simes J, Voysey M, O'Connell R, et al. A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS One 2010;5:e8580
18. Wierzbicki AS. Fields of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006;60:442-449
19. The ACCORD study group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
20. Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of longterm randomized placebo-controlled clinical trials. Am Heart J 2007; 154:943-953
21. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-1878
22. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462-468
23. Vega GL, Grundy SM. Effect of statins on metabolism of apo-Bcontaining lipoproteins in hypertriglyceridemic men. Am J Cardiol 1998; 81:36B-42B
24. Bilz S, Wagner S, Schmitz M, et al. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 2004;45:174-185
25. Watts GF, Barrett PH, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003;52:803-811
26. Sniderman AD, St-Pierre AC, Cantin B, et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003;91:1173-1177
27. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-458
28. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66B-9B
29. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-133
30. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-917
31. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate\+statin versus gemfibrozil\+any statin. Am J Cardiol 2005;95:120-122
32. Lipscombe J, Lewis GF, Cattran D, et al. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001;55:39-44
33. Ansquer JC, Dalton RN, Causse E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008;51:904-913